Vertex Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812" ], "revenue_estimate": [ 13038, 14395.07, 16154.12 ], "ebit_estimate": [ 5507.53, 6396.06, 7384.6 ], "ebitda_estimate": [ 5683.89, 6780.99, 7940.75 ], "net_income_estimate": [ 4902.09, 5696.85, 6622.79 ], "per_share_eps_estimate": [ 17.66, 19.66, 23.22 ], "eps_nri_estimate": [ 19.1, 21.87, 25.54 ], "dividend_estimate": [ null, null, null ], "book_value_per_share_estimate": [ 89.22, 105.8, 124.57 ], "pretax_income_estimate": [ 6040.24, 6952.65, 8121.39 ], "operating_cash_flow_per_share_estimate": [ 23.5, 23.39, 25.94 ], "roa_estimate": [ 14.5, 13.9, 13.9 ], "roe_estimate": [ 22.94, 21.26, 20.34 ], "gross_margin_estimate": [ 87.07, 87.83, 88.33 ], "operating_cash_flow_estimate": [ 6020.7, 5992.52, 6645.83 ], "pettm_estimate": [ 24.6, 22.1, 18.7 ], "long_term_growth_rate_mean": 11.85, "long_term_revenue_growth_rate_mean": "10.41", "future_per_share_eps_estimate_growth": 14.51, "future_eps_nri_estimate_growth": 11.85, "future_revenue_estimate_growth": 10.41, "future_ebit_estimate_growth": 16.57, "future_ebitda_estimate_growth": 17.89, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 18.51, "future_pretax_income_estimate_growth": 19.94, "future_book_value_per_share_estimate_growth": 19.17, "future_roa_estimate_growth": -5.26, "future_roe_estimate_growth": -3.77, "future_gross_margin_estimate_growth": 0.81, "future_operating_cash_flow_per_share_estimate_growth": 20.08 }

{ "date": [ "202603", "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 3065.94, 3218.02, 3329.06, 3439.9, 3321.15, 3467.45, 3631.91, 3725.96 ], "ebit_estimate": [ 1251.35, 1348.98, 1406.1, 1432.53, 1418.78, 1539.62, 1706.17, 1774.74 ], "ebitda_estimate": [ 1330.63, 1426.66, 1526.39, 1467.9, 1531, 1528, 1711, 1893 ], "net_income_estimate": [ 1141.01, 1224.16, 1274.06, 1299.57, 1280.5, 1382.7, 1526.44, 1585.41 ], "per_share_eps_estimate": [ 3.96, 4.42, 4.62, 4.82, 4.26, 4.69, 5.14, 5.18 ], "eps_nri_estimate": [ 4.41, 4.73, 4.94, 5.06, 4.76, 5.15, 5.7, 5.93 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ 1398.49, 1493.47, 1555.22, 1598.44, 1540.57, 1674.89, 1838.23, 1870.15 ], "operating_cash_flow_per_share_estimate": [ 27.2, 24.06, -2.69, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 86.52, 86.57, 86.76, 87.14, 86, 86, 86, 86 ], "operating_cash_flow_estimate": [ 6968.64, 6164.17, -689.18, null, null, null, null, null ], "pettm_estimate": [ 24.38, 23.98, 23.63, 22.97, 22.54, null, null, null ], "long_term_growth_rate_mean": 11.85, "long_term_revenue_growth_rate_mean": "10.41", "future_per_share_eps_estimate_growth": 14.51, "future_eps_nri_estimate_growth": 11.85, "future_revenue_estimate_growth": 10.41, "future_ebit_estimate_growth": 16.57, "future_ebitda_estimate_growth": 17.89, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 18.51, "future_pretax_income_estimate_growth": 19.94, "future_book_value_per_share_estimate_growth": 19.17, "future_roa_estimate_growth": -5.26, "future_roe_estimate_growth": -3.77, "future_gross_margin_estimate_growth": 0.81, "future_operating_cash_flow_per_share_estimate_growth": 20.08 }